Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ERLOTINIB for Non-small cell lung cancer metastatic: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 290 adverse event reports in the FDA FAERS database where ERLOTINIB was used for Non-small cell lung cancer metastatic.

Most Reported Side Effects for ERLOTINIB

Side Effect Reports % Deaths Hosp.
Death 5,000 22.3% 4,996 386
Rash 4,648 20.7% 580 485
Diarrhoea 3,448 15.3% 462 598
Fatigue 1,548 6.9% 392 246
Nausea 1,366 6.1% 284 290
Drug ineffective 1,207 5.4% 159 101
Off label use 1,190 5.3% 809 198
Decreased appetite 998 4.4% 249 234
Malignant neoplasm progression 954 4.3% 494 230
Dry skin 953 4.2% 57 83
Disease progression 910 4.1% 246 93
Pruritus 830 3.7% 68 82
Vomiting 820 3.7% 199 271
Asthenia 757 3.4% 281 230
Dyspnoea 738 3.3% 265 283

Other Indications for ERLOTINIB

Lung neoplasm malignant (9,207) Non-small cell lung cancer (3,359) Product used for unknown indication (3,040) Pancreatic carcinoma (1,089) Malignant respiratory tract neoplasm (876) Lung adenocarcinoma (841) Neoplasm malignant (565) Bronchial carcinoma (397) Lung adenocarcinoma stage iv (203) Bone cancer (174)

Other Drugs Used for Non-small cell lung cancer metastatic

CARBOPLATIN (1,629) PEMETREXED (1,426) PEMBROLIZUMAB (1,417) OSIMERTINIB (1,056) ATEZOLIZUMAB (870) PACLITAXEL (671) ALECTINIB (627) BEVACIZUMAB (519) NIVOLUMAB (488) CRIZOTINIB (429)

Related Pages

ERLOTINIB Full Profile All Non-small cell lung cancer metastatic Drugs ERLOTINIB Demographics ERLOTINIB Timeline